Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | PAM | P19021 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437701 | 0.94 | DGKA (0.70) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL7282921 | 0.94 | DGKA (0.59) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL5256636 | 0.94 | DGKA (0.59) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL7838818 | 0.92 | DGKA (0.62) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL7837625 | 0.92 | DGKA (0.62) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL7828305 | 0.92 | DGKA (0.74) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL7838151 | 0.92 | DGKA (0.74) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL7838591 | 0.92 | DGKA (0.62) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL7757774 | 0.92 | DGKA (0.74) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL7829238 | 0.92 | DGKA (0.62) | DGKAPRSS1PRSS2PRSS3NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796330-B2 | Inhibitors of histone deacetylase and prodrugs thereof | METHYLGENE INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-8759400-B2 | Histone deacetylase inhibitors for enhancing activity of antifungal agents | METHYLGENE INC. (CA) | 2014-06-24 | — | — | US | disclosed |
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | METHYLGENE INC. (CA) | 2014-03-20 | — | — | US | disclosed |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2014-01-23 | — | — | US | disclosed |
| EP-2605770-A1 | ANTIFUNGAL AGENTS AND USES THEREOF | MethylGene Inc. (CA) | 2013-06-26 | — | — | EP | disclosed |
| EP-2573069-A2 | Inhibitors of histone deacetylase and prodrugs thereof | MethylGene Inc. (CA) | 2013-03-27 | — | — | EP | disclosed |
| WO-2012021982-A1 | ANTIFUNGAL AGENTS AND USES THEREOF | METHYLGENE INC. (CA) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046331-A1 | Antifungal Agents and Uses Thereof | METHYLGENE INC. (CA) | 2012-02-23 | — | — | US | disclosed |
| EP-1973872-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | Methylgene, Inc. (CA) | 2008-10-01 | — | — | EP | disclosed |
| EP-1963258-A2 | HISTONE DEACETYLASE INHIBITORS FOR ENHANCING ACTIVITY OF ANTIFUNGAL AGENTS | Methylgene, Inc. (CA) | 2008-09-03 | — | — | EP | disclosed |
| US-5278337-A | Enantiomeric resolution of aryl-substituted aliphatic carboxylic acids | ETHYL CORPORATION (US) | 1994-01-11 | — | — | US | disclosed |
| US-5260482-A | Enantiomeric resolution | ETHYL CORPORATION (US) | 1993-11-09 | — | — | US | disclosed |
| US-5256816-A | Enantiomeric resolution | ETHYL CORPORATION (US) | 1993-10-26 | — | — | US | disclosed |
| US-5254584-A | Controlling phytopathogens | ROHM AND HAAS COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0565132-A2 | Benzoheterocyclic compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-13 | — | — | EP | disclosed |
| US-5248813-A | Enantiomeric resolution | ETHYL CORPORATION (US) | 1993-09-28 | — | — | US | disclosed |
| US-4808620-A | ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETIC, ANTIALLERGENS, ANTIARTHRITIC, ANTIRHEUMATIC AGENTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-02-28 | — | — | US | disclosed |
| EP-0287951-A2 | 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-10-26 | — | — | EP | disclosed |
| EP-0254241-A1 | Pyrazolopyridine compounds, their preparation and use | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1988-01-27 | — | — | EP | disclosed |
| US-4443435-A | ANTICARCINOGENS, HYPOTENSIVE AGENTS, HYPERTHYROIDISM | MERCK & CO., INC. (US) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | HDAC1, HDAC5, HDAC7 | DGKA 3626/4885PRSS1 1053/4885PRSS2 1515/4885 |
| US-20120046331-A1 | Antifungal Agents and Uses Thereof | PRKDC, PIK3C3, KRT18 | DGKA 1272/4885PRSS1 1258/4885PRSS2 1394/4885 |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | HDAC1, HDAC3, HDAC11 | DGKA 2896/4885PRSS1 870/4885PRSS2 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.